Gene · 1633
Papers2,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,658
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular targets and mechanisms involved in the action of Banxia Shumi decoction in insomnia treatment. | Medicine (Baltimore) | 2023 | 36897671 | PubTator, text mining | PubMed |
| Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms. | Leuk Lymphoma | 2023 | 36896478 | PubTator, text mining | PubMed |
| NUDT22 promotes cancer growth through pyrimidine salvage. | Oncogene | 2023 | 36871087 | PubTator, text mining | PubMed |
| Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. | Lancet Oncol | 2023 | 36858729 | PubTator, text mining | PubMed |
| Implication of 99mTc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells. | J Immunother Cancer | 2023 | 36858461 | PubTator, text mining | PubMed |
| A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. | Vaccines (Basel) | 2023 | 36851211 | PubTator, text mining | PubMed |
| Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines. | Int J Mol Sci | 2023 | 36834962 | PubTator, text mining | PubMed |
| microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer. | Cancers (Basel) | 2023 | 36831572 | PubTator, text mining | PubMed |
| Metabolic Reprogramming of Breast Tumor-Educated Macrophages Revealed by NMR Metabolomics. | Cancers (Basel) | 2023 | 36831553 | PubTator, text mining | PubMed |
| Labeling T Cells to Track Immune Response to Immunotherapy in Glioblastoma. | Tomography | 2023 | 36828374 | PubTator, text mining | PubMed |
| Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine. | Cancer Med | 2023 | 36808479 | PubTator, text mining | PubMed |
| Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. | J Natl Med Assoc | 2023 | 36801148 | PubTator, text mining | PubMed |
| Modulating epigenetic modifications for cancer therapy (Review). | Oncol Rep | 2023 | 36799181 | PubTator, text mining | PubMed |
| The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. | Int J Mol Sci | 2023 | 36769116 | PubTator, text mining | PubMed |
| Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer. | Cancers (Basel) | 2023 | 36765737 | PubTator, text mining | PubMed |
| Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC). | Cancers (Basel) | 2023 | 36765586 | PubTator, text mining | PubMed |
| Activity-based CRISPR scanning uncovers allostery in DNA methylation maintenance machinery. | Elife | 2023 | 36762644 | PubTator, text mining | PubMed |
| MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance. | Mol Cancer Res | 2023 | 36757299 | PubTator, text mining | PubMed |
| Factors Influencing Sarcopenic Changes in YUBI-WAKKA Finger-Ring Test Results After One Year: A Retrospective Observational Study. | J Clin Med Res | 2023 | 36755766 | PubTator, text mining | PubMed |
| Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. | Mol Cell | 2023 | 36736316 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1633/papers?page=10